Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494.
McInnes et al. assessed the efficacy of guselkumab over 48 weeks in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors. The results demonstrated consistent improvements in joint, skin, and patient-reported outcomes across all baseline-defined subgroups. Guselkumab showed greater efficacy compared with placebo at Week 24, with responses maintained or improved through Week 48.
The study aimed to determine whether baseline patient characteristics influenced guselkumab’s efficacy. The findings confirmed that treatment response was consistent across subgroups stratified by age, sex, BMI, and prior therapies, supporting guselkumab as an effective option for diverse patient profiles.
Keywords:
